CROI 2023: more than 20 research projects supported by the agency presented

10 February 2023
CROI 2023

CROI, the International Conference on Retroviruses and Opportunistic Infections, takes place February 19-22, 2023, in Seattle and is accessible online. Twenty-three abstracts supported by the agency have been selected for presentation.


What to remember about CROI 2023?

Find on the website of our partner* the articles dedicated to the event:

* Since 2023, the media and the agency ANRS | Malaladies infectieuses émergentes have been working together to create content for their respective websites on current research on HIV/AIDS and emerging infectious diseases. This digital content respects the independent and demanding editorial line of and puts the results of research supported by the agency into perspective.



Oral Presentations:

  • ANRS 174 DOXYVAC: An open-label randomized trial to prevent STI in MSM on PrEP by Jean-Michel Molina on Monday, February 20 (schedule to come)
  • Improved strategy to prevent HIV postnatal transmission, a randomized trial (PROMISE-EPI) by Nicolas Nagot on Monday, February 20 (11:08 a.m. - 11:16 a.m. Seattle time, 8:08 p.m. - 8:16 p.m. Paris time)
  • Impact of vaccination on mpox incidence in MSM on PrEP in the ANRS 174 DOXYVAC trial by Jade Ghosn on Wednesday, February 22 (schedule to come)

Posters :

Nicolas Nagot Maternal HIV viral load threshold for guiding extended infant prophylaxis initiation (PROMISE-EPI)
Yves Lévy CD40.HIVRI.ENV vaccine induces strong and durable immune responses: ANRS/VRI06 TRIAL
Laury Nguema CD40.SARS-CoV2 vaccine, but not mRNA, induces specific CD8+ T memory stem cells
Rodolph Thiebaut Which endpoint to choose during antiretroviral treatment interruption?
Julie Longobardi 12-month humoral response after mRNA COVID-19 vaccination in people living with HIV (COV-POPART)
Cédric Laouénan MOSAIC Clade 2B mpox cohort study: clinical characterisation and outcomes (MOSAIC)
Charlotte Charpentier/Diane Descamps Higher spike genetic diversity of Delta/Omicron variants in immonocompromised hosts (EMERGEN)
Elisa Teyssou SARS-CoV-2 variants-dependant inflammasome activation (EMERGEN)
Valentin Leducq SARS-COV-2 variants' temporal and VL distributions in immunocompromised patients (EMERGEN)
Rodolph Thiebaut Effects of public health interventions against COVID-19 in France
Lisa Chakrabarti Development of a lymphoid organ-chip to evaluate COVID vaccine boosting strategies
Charlotte Charpentier High prevalence of HPV other STI, and anal lesions among MSM in Togo
Charlotte Charpentier Methylation markers on anal smears are associated with higher anal cancer risk
Marc Wirden Epidemiological and molecular evolution of the HIV-1 CRF94: birth of the CRF132
Thierry Tiendrebeogo Predictors of transitioning to a first line Dolutegravir regimen in West Africa (travaux de la cohorte IeDEA coordonnée par PAC-CI)
Thierry Tiendrebeogo Weight gain following switch to Dolutegravir among adult HIV cohorts in West Africa (travaux de la cohorte IeDEA coordonnée par PAC-CI)
Quentin Le Hingrat Mpox virus sequences diversity in Paris area during the 2022 outbreak
Céline Roy PAGE-B Score to estimate the hepatocellular carcinoma risk in people with HIV and HBV (issu de CO3 AQUITAINE)
Céline Roy Contribution of alcohol use un HIV/HCV co-infection to all-cause mortality (issu de CO3 AQUITAINE)
Céline Roy Causes of death among adults with HIV on ART in Europe and North America 1996-2019 (issu de CO3 AQUITAINE)



Find out more:
CROI – Conference on Retroviruses and Opportunistic Infections :

Press contact: